Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07733180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

Name: A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC — clinical trial record (NCT07733180)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorBeOne Medicines

Started2026-09-14

View on ClinicalTrials.gov ↗

Amendment history

2026-09-19

Recruitment opened

BeOne Medicines

59 trials monitored

See 7 trials at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line treatment in Japanese participants with previously untreated, unresectable locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC).

Trial Details

NCT Number	NCT07733180
Lead Sponsor	BeOne Medicines
Conditions	Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Enrollment	30 participants
Start Date	2026-09-14
Primary Completion	2028-02-28 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-09-28